Indicators of cure for women living after uterine and ovarian cancers: a population-based study
- Autori: Giudici, F.; De Paoli, A.; Toffolutti, F.; Guzzinati, S.; Francisci, S.; Bucchi, L.; Gatta, G.; Demuru, E.; Mallone, S.; Cin, A.D.; Caldarella, A.; Cuccaro, F.; Migliore, E.; Gambino, M.L.; Ravaioli, A.; Puppo, A.; Ferrante, M.; Carrozzi, G.; Stracci, F.; Musolino, A.; Gasparotti, C.; Cavallo, R.; Mazzucco, W.; Vitale, M.F.; Cascone, G.; Ballotari, P.; Ferretti, S.; Mangone, L.; Rizzello, R.V.; Sampietro, G.; Mian, M.; Boschetti, L.; Galasso, R.; Bella, F.; Piras, D.; Sessa, A.; Seghini, P.; Fanetti, A.C.; Pinna, P.; De Angelis, R.; Serraino, D.; Maso, L.D.; Working Group, A.
- Anno di pubblicazione: 2024
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/664654
Abstract
This study aims to estimate long-term survival, cancer prevalence, and several cure indicators for Italian women with gynaecological cancers. Thirty-one cancer registries, representing 47% of the Italian female population, were included. Mixture cure models were used to estimate Net Survival (NS), Cure Fraction, Time To Cure (5-year conditional NS>95%), Cure Prevalence (women who will not die of cancer), and Already Cured (living longer than Time to Cure). In 2018, 0.4% (121,704) of Italian women were alive after corpus uteri cancer, 0.2% (52,551) after cervical, and 0.2% (52,153) after ovarian cancer. More than 90% of patients with uterine cancers and 83% with ovarian cancer will not die from their neoplasm (Cure Prevalence). Women with gynaecological cancers have a residual excess risk of death <5% after 5 years since diagnosis. The Cure Fraction was 69% for corpus uteri, 32% for ovarian, and 58% for cervical cancer patients. Time To Cure was ≤10 years for women with gynaecological cancers aged <55 years. 74% of patients with cervical cancer, 63% with corpus uteri cancer, and 55% with ovarian cancer were Already Cured. These results will contribute to improving follow-up programs for women with gynaecological cancers and supporting efforts against discrimination of already cured ones.